A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis

XOMA (US) LLC0 sites45 target enrollmentJanuary 16, 2003

ConditionsPsoriatic Arthritis

Drugsefalizumab

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Psoriatic Arthritis
Sponsor: XOMA (US) LLC
Enrollment: 45
Status: Completed
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)

Detailed Description

A phase II, randomized, double-blind, placebo-controlled study to: 1. Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with psoriatic arthritis (PsA). 2. Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of subjects with PsA

Registry

clinicaltrials.gov

Start Date

January 16, 2003

End Date

February 2004

Last Updated

20 years ago

Study Type

Interventional

Study Design

Single Group